Search Results - "DeRemer, Susan J."

  • Showing 1 - 7 results of 7
Refine Results
  1. 1

    ACEMg Diet Supplement Modifies Progression of Hereditary Deafness by Green, Kari L., Swiderski, Donald L., Prieskorn, Diane M., DeRemer, Susan J., Beyer, Lisa A., Miller, Josef M., Green, Glenn E., Raphael, Yehoash

    Published in Scientific reports (11-03-2016)
    “…Dietary supplements consisting of beta-carotene (precursor to vitamin A), vitamins C and E and the mineral magnesium (ACEMg) can be beneficial for reducing…”
    Get full text
    Journal Article
  2. 2

    Correction: Corrigendum: ACEMg Diet Supplement Modifies Progression of Hereditary Deafness by Green, Kari L., Swiderski, Donald L., Prieskorn, Diane M., DeRemer, Susan J., Beyer, Lisa A., Miller, Josef M., Green, Glenn E., Raphael, Yehoash

    Published in Scientific reports (20-04-2016)
    “…Scientific Reports 6: Article number: 22690; published online: 11 March 2016; updated: 20 April 2016 This Article contains errors in the legend of Fig. 5…”
    Get full text
    Journal Article
  3. 3

    Regional Pharmacokinetics of Amifostine in Anesthetized Dogs: Role of the Liver, Gastrointestinal Tract, Lungs, and Kidneys by LEVI, Micha, KNOL, James A, ENSMINGER, William D, DEREMER, Susan J, CHUNZHI DOU, LUNTE, Susan M, BONNER, Heather S, SHAW, Leslie M, SMITH, David E

    Published in Drug metabolism and disposition (01-12-2002)
    “…Amifostine is a prodrug in which selectivity is largely determined by the preferential formation and uptake of its cytoprotective metabolite, WR-1065, in…”
    Get full text
    Journal Article
  4. 4
  5. 5

    Disposition of WR-1065 in the liver of tumor-bearing rats following regional vs systemic administration of amifostine by Levi, Micha, DeRemer, Susan J., Dou, Chunzhi, Ensminger, William D., Smith, David E.

    Published in Biopharmaceutics & drug disposition (01-01-2004)
    “…Purpose—Amifostine is a prodrug in which selectivity is largely determined by the preferential formation and uptake of its cytoprotective metabolite, WR‐1065,…”
    Get full text
    Journal Article
  6. 6

    Regional pharmacokinetics of 5-bromo-2'-deoxyuridine and 5-fluorouracil in dogs : Hepatic arterial versus portal venous infusions by KUAN, H.-Y, SMITH, D. E, ENSMINGER, W. D, KNOL, J. A, DEREMER, S. J, YANG, Z, STETSON, P. L

    Published in Cancer research (Chicago, Ill.) (15-10-1996)
    “…The purpose of this study was to determine the effect of route of hepatic administration of drug on the regional pharmacokinetics and systemic exposure of…”
    Get full text
    Journal Article
  7. 7

    Regional pharmacokinetics of 5-fluorouracil in dogs : Role of the liver, gastrointestinal tract, and lungs by KUAN, H.-Y, SMITH, D. E, ENSMINGER, W. D, KNOL, J. A, DEREMER, S. J, ZHAOMIN YANG, STETSON, P. L

    Published in Cancer research (Chicago, Ill.) (15-04-1998)
    “…The purpose of this study was to determine the presence and extent of pulmonary elimination for 5-fluorouracil (FUra). A secondary aim was to characterize the…”
    Get full text
    Journal Article